Literature DB >> 26291795

Hyperprolactinemia: pathophysiology and therapeutic approach.

Anna Capozzi1, Giovanni Scambia, Alfredo Pontecorvi, Stefano Lello.   

Abstract

Prolactin (PRL) is a hormone, mainly secreted by lactotroph cells of the anterior pituitary gland. Recent studies have shown it may also be produced by many extrapituitary cells. Its well-recognized PRL plays an important role in lactation during pregnancy, but it is involved in other biological functions such as angiogenesis, immunoregulation and osmoregulation. Hyperprolactinemia is a typical condition producing reproductive dysfunction in both sexes, resulting in hypogonadism, infertility and galactorrhea. It may be also asymptomatic. Lactotroph adenomas (prolactinoma) is one of the most common cause of PRL excess, representing approximately 40% of all pituitary tumors. Several other conditions should be excluded before a clear diagnosis of hyperprolactinemia is made. Hyperprolactinemia may be secondary to pharmacological or pathological interruption of hypothalamic-pituitary dopaminergic pathways or idiopathic. Stress, renal failure or hypothyroidism are other frequent conditions to exclude in patients with hyperprolactinemia. We will review biochemical characteristics and physiological functions of that hormone. Clinical and pharmacological approach to hyperprolactinemia will also be discussed.

Entities:  

Keywords:  Cabergoline; dopamine agonist; hyperprolactinemia; oligomenorrhea

Mesh:

Substances:

Year:  2015        PMID: 26291795     DOI: 10.3109/09513590.2015.1017810

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  24 in total

1.  Introduction of Female Reproductive Processes and Reproductive Diseases.

Authors:  Jiajia Zhang; Jiao Li; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.

Authors:  Hai Yan Huang; Weiwei Zhai; Hao Tang; Guo Zhen Hui; Zhe Bao Wu
Journal:  Endocrine       Date:  2018-09-20       Impact factor: 3.633

3.  Conditional Deletion of the Prolactin Receptor Reveals Functional Subpopulations of Dopamine Neurons in the Arcuate Nucleus of the Hypothalamus.

Authors:  Rosemary S E Brown; Ilona C Kokay; Hollian R Phillipps; Siew Hoong Yip; Papillon Gustafson; Amanda Wyatt; Caroline M Larsen; Penelope Knowles; Sharon R Ladyman; Paul LeTissier; David R Grattan
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

4.  HYPERPROLACTINEMIA IN A TRANSGENDER MALE.

Authors:  Sapna Patel; Jessica Abramowitz
Journal:  AACE Clin Case Rep       Date:  2020-09-26

5.  Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial.

Authors:  Mervat Ali Mohamed Elsersy
Journal:  J Obstet Gynaecol India       Date:  2017-06-24

6.  Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Authors:  Yinxing Huang; Chenyu Ding; Fangfang Zhang; Deyong Xiao; Lin Zhao; Shousen Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

7.  Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.

Authors:  Hai Yan Huang; Shao Jian Lin; Wei Guo Zhao; Zhe Bao Wu
Journal:  Metab Brain Dis       Date:  2018-03-15       Impact factor: 3.584

Review 8.  Pituitary Adenomas: From Diagnosis to Therapeutics.

Authors:  Samridhi Banskota; David C Adamson
Journal:  Biomedicines       Date:  2021-04-30

9.  Utility of Cannulated Prolactin to Exclude Stress Hyperprolactinemia in Patients with Persistent Mild Hyperprolactinemia.

Authors:  Raya Almazrouei; Shamaila Zaman; Florian Wernig; Karim Meeran
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-06-22

Review 10.  Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology.

Authors:  Andrea I Loewendorf; Anna Matynia; Hakob Saribekyan; Noah Gross; Marie Csete; Mike Harrington
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.